Phase III Cisplatin+Paclitaxel +/- Bevacizumab Vs Topotecan+Paclitaxel +/- Bevacizumab Cervix Cancer

Trial ID or NCT#

NCT00803062

Status

not recruiting iconNOT RECRUITING

Purpose

This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical cancer that has come back or is persistent. Drugs used in chemotherapy, such as paclitaxel, cisplatin, and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether paclitaxel is more effective when given together with cisplatin or topotecan with or without bevacizumab in treating patients with cervical cancer.

Official Title

A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Eligibility Criteria

Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No

Investigator(s)

Jonathan S Berek
Jonathan S Berek
Gynecologic oncologist
Laurie Kraus Lacob Professor

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061